<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Vertex Pharmaceuticals Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/vertex-pharmaceuticals-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals</title>
		<link>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883</link>
		<comments>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:34:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89883</guid>
		<description><![CDATA[The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&#38;A) deals have taken place in the pharma sector over the last couple of years. With most of the big pharma players already facing or likely to face generic threats to their key products, the companies are resorting to M&#38;As and in-licensing deals to counter the loss of revenues that will arise following the genericization of its key drugs. Pharma major Bristol-Myers is no exception as the generic threat looms over many of its key drugs, including the blockbuster blood-thinner Plavix, co-developed with Sanofi (SNY). Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions, and is introducing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Spotlight on Hepatitis-C Market</title>
		<link>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141</link>
		<comments>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88141</guid>
		<description><![CDATA[Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies &#8211; as evident by the deals being signed for the development of drugs for the treatment of HCV. We are talking about the recent announcements made by big players like Johnson &#38; Johnson (JNJ), Bristol-Myers Squibb (BMY) and Gilead Sciences, Inc. (GILD). All three companies have made it clear they want a piece of the HCV market pie. Johnson &#38; Johnson’s Tibotec Pharmaceuticals and Bristol-Myers Squibb recently announced that they have decided to join forces for the development of Bristol-Myers’ daclatasvir (BMS-790052) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales</title>
		<link>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343</link>
		<comments>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343#comments</comments>
		<pubDate>Wed, 02 Nov 2011 17:08:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86343</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents and the year-ago loss of 99 cents. Increased revenues from the sale of hepatitis C virus (HCV) treatment, Incivek (telaprevir) helped record positive earnings. Revenues Riding on the strong sales of Incivek, which was launched in the second quarter of 2011, Vertex Pharma reported total revenue of $659.2 million, almost double the Zacks Consensus Estimate of $342 million and significantly above the year-ago figure of $23.8 million. Vertex Pharma’s third quarter revenues consisted of revenue earned from the sale of Incivek ($419.6 million), royalty revenue (up 4.5% to $8.5 million) and collaborative revenue (up 137.9% to $231.1 million). Collaborative revenue for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut</title>
		<link>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114</link>
		<comments>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114#comments</comments>
		<pubDate>Tue, 27 Sep 2011 20:45:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84114</guid>
		<description><![CDATA[Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline at Enzon was reduced drastically in the last few months. During the second quarter, Enzon announced that it will no longer develop three messenger ribonucleic acid (mRNA) antagonists utilizing the LNA technology and returned the rights to Santaris. The mRNA antagonists, all of which were in phase I trials, were hypoxia-inducible factor-1 alpha (HIF-1 a) indicated for tumors and lymphoma, survivin indicated for cancer and pediatric patients with relapse acute lymphoblastic leukemia and androgen receptor (AR) for castration-resistant prostate cancer (CRPC). Earlier, in mid-May 2011, Enzon announced plans to halt the development of its lead pipeline candidate PEG-SN38 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Presents HCV Data</title>
		<link>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567</link>
		<comments>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:50:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83567</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care) for treating patients suffering from the hepatitis C virus (HCV). Bristol-Myers presented data from the mid-stage study at the 51st interscience conference on antimicrobial agents and chemotherapy held in the US. The double-blind study evaluated BMS-790052 at three doses (3 mg, 10 mg or 60 mg) in treatment-naïve patients infected with genotype 1 chronic HCV. Results from the study revealed that the rate of SVR24 (sustained virologic response – absence of detectable HCV at 24 weeks post treatment ) achieved by patients treated with a combination of BMS-790052, PEG-interferon alfa and ribavirin was higher across all evaluated doses than those receiving placebo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell</title>
		<link>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032</link>
		<comments>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:49:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83032</guid>
		<description><![CDATA[We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its lead pipeline compound PEG-SN38 (EZN-2208), a PEGylated version of the active metabolite of the cancer drug, irinotecan, for the treatment of metastatic colorectal cancer (mCRC). Enzon decided to halt development as the company intends to focus its resources on other areas with nearer-term commercial potential. The discontinuation of development of PEG-SN38 for mCRC is a disappointment, leaving the company with just one clinical program in mid-stage development (PEG-SN38 for metastatic breast cancer) and all others in early stages of development. The company’s pipeline candidates include PEG-SN38, hypoxia-inducible factor1 (HIF-1) alpha, survivin antagonists and multiple messenger RNA (mRNA) antagonists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Reports Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979</link>
		<comments>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:19:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BID]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[Sotheby's]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82979</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) reported positive data from a mid-stage trial on VX-509, which is being studied for the treatment of moderate to severe rheumatoid arthritis (RA). The 12-week study, which evaluated four doses of the candidate, met both the primary endpoints. Data from the two highest dose (100 mg and 150 mg) treatment arms demonstrated significant improvement in the proportion of people who achieved at least a 20% improvement in the signs and symptoms of RA (ACR20), and a statistically significant improvement from baseline in Disease Activity Score 28 (DAS28), compared to placebo. The study also met the secondary endpoints (ACR50 and ACR70) of achieving statistically significant responses compared to placebo. On the basis of the data from the phase IIa study, Vertex Pharma plans to initiate a six-month ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals&#8217; Weak Top Line Widens Loss</title>
		<link>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950</link>
		<comments>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:23:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80950</guid>
		<description><![CDATA[Enzon Pharmaceuticals’ (ENZN) second quarter 2011 net loss of 12 cents per share (excluding restructuring charge) was wider than the loss of 8 cents suffered in the year-ago quarter as the decline in royalty revenue neutralized the savings from cost-cutting initiatives. The Zacks Consensus Estimate indicated a break-even for the company. Total revenue at Enzon was $9.6 million, sharply down 30% year over year due to the decline in royalty revenue. Revenue was also much below the Zacks Consensus Estimate of $15 million. Royalty revenue in the quarter dropped around 13% to $9.2 million. Enzon earns the majority of its royalty revenue from the sale of PegIntron, marketed by Merck &#38; Co. (MRK), for treating patients suffering from hepatitis C virus (HCV). The decline in royalty revenue in the reported ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek</title>
		<link>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310</link>
		<comments>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310#comments</comments>
		<pubDate>Mon, 01 Aug 2011 16:40:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80310</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago loss of 83 cents. Increased revenues from the sale of hepatitis C virus (HCV) candidate, Incivek (telaprevir) helped reduce the loss. Revenues Riding on the strong sales of Incivek, which was launched during the quarter, total revenue soared 262% to $114.4 million, surpassing the Zacks Consensus Estimate of $54 million. Vertex Pharma’s first quarter revenues consisted of revenue earned from the sale of Incivek ($74.5 million), royalty revenue (up 37.8% to $10.0 million) and collaborative revenue (up 22.7% to $30.0 million). The company receives royalty from GlaxoSmithKline plc (GSK) on sales of Lexiva, a HIV protease inhibitor. Collaborative revenue consists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MHS) Medco Health Solutions to Better Tackle Hepatitis C</title>
		<link>http://www.stockbloghub.com/2011/07/06/mhs-medco-health-solutions-to-better-tackle-hepatitis-c/78506</link>
		<comments>http://www.stockbloghub.com/2011/07/06/mhs-medco-health-solutions-to-better-tackle-hepatitis-c/78506#comments</comments>
		<pubDate>Wed, 06 Jul 2011 21:19:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78506</guid>
		<description><![CDATA[Medco Health Solutions (MHS) is making attempts to curtail costs of treating patients suffering from hepatitis C (HCV). The company’s specialty pharmacy segment, Accredo Health Group, considers patient adherence to the treatment most significant as any contrary behavior could lead to liver cirrhosis and certain cancers. Accredo is optimistic about two new HCV medications &#8212; boceprevir and teleprevir &#8212; although the treatment process is quite complex and requires greater degree of adherence. In May 2011, Merck (MRK) received approval from the US Food and Drug Administration (FDA) for Victrelis (boceprevir) to treat chronic hepatitis C (CHC). The drug is approved for the treatment of CHC genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients who were left untreated or failed previous interferon and ribavirin therapy. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/mhs-medco-health-solutions-to-better-tackle-hepatitis-c/78506/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Get Positive Data on Incivek</title>
		<link>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386</link>
		<comments>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386#comments</comments>
		<pubDate>Fri, 24 Jun 2011 20:36:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77386</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New England Journal of Medicine. The trial results demonstrated that when patients suffering from chronic hepatitis C (HCV) were given Incivek combination therapy, they experienced significant improvement in sustained viral response (SVR) rates, as compared to those who received pegylated-interferon and ribavirin alone. In the ADVANCE study, Incivek combination therapy demonstrated the aforesaid results in new patients, while the REALIZE study consisted of treatment-failed patients. We note that in the ADVANCE study, majority of the patients treated with Incivek combination therapy completed the treatment in 24 weeks, which is half the time needed in the pegylated-interferon and ribavirin arm. Further, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Posts Wider Loss</title>
		<link>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436</link>
		<comments>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436#comments</comments>
		<pubDate>Sun, 08 May 2011 15:51:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73436</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted first-quarter 2011 loss (including stock-based compensation expense) of $1.05 per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 80 cents. Increased expenses related to the potential launch of hepatitis C virus (HCV) candidate, Incivek (proposed US trade name for telaprevir), led to the higher loss. Revenues Revenues for the reported quarter increased 229% to $73.7 million, exceeding the Zacks Consensus Estimate of $25 million. First quarter revenues included a $50 million milestone payment received from Johnson &#38; Johnson (JNJ), on the acceptance of the Marketing Authorization Application (MAA) for Incivek in Europe. Vertex Pharma’s first quarter revenues consisted of royalty revenues (down 5.4% to $6.1 million) and collaborative revenues (up 321.9% to $67.6 million). The company receives royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Analyst Holds Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/04/09/enzn-enzon-pharmaceuticals-analyst-holds-shares-at-neutral/70655</link>
		<comments>http://www.stockbloghub.com/2011/04/09/enzn-enzon-pharmaceuticals-analyst-holds-shares-at-neutral/70655#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:27:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70655</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Enzon Pharmaceuticals, Inc. (ENZN) with a target price of $12.00 after announcement of fourth quarter and full year 2010 results. Enzon Pharmaceuticals’ fourth quarter 2010 net loss of 14 cents per share (excluding special items) was wider than the Zacks Consensus Estimate, which indicated a loss of 8 cents. The loss, however, compared favorably with a loss of 21 cents suffered in the year-ago quarter.  On a reported basis (including special items), the company saw a loss from continuing operations of 17 cents as against a loss of 32 cents per share in the year-ago quarter. The narrower loss in the quarter emanated from the divestiture of the specialty pharmaceutical business (January 2010) and subsequent cost savings at Enzon. The debt burden at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/enzn-enzon-pharmaceuticals-analyst-holds-shares-at-neutral/70655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CHS) Company News for February 24, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/02/24/chs-company-news-for-february-24-2011-corporate-summary/67526</link>
		<comments>http://www.stockbloghub.com/2011/02/24/chs-company-news-for-february-24-2011-corporate-summary/67526#comments</comments>
		<pubDate>Thu, 24 Feb 2011 18:36:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Apparel Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Chico's FAS Inc.]]></category>
		<category><![CDATA[CHS]]></category>
		<category><![CDATA[DEP]]></category>
		<category><![CDATA[Duncan Energy Partners LP]]></category>
		<category><![CDATA[Enterprise Products Partners Lp]]></category>
		<category><![CDATA[EPD]]></category>
		<category><![CDATA[Garmin Limited]]></category>
		<category><![CDATA[GRMN]]></category>
		<category><![CDATA[Limited Brands Inc.]]></category>
		<category><![CDATA[LTD]]></category>
		<category><![CDATA[The TJX Companies Inc.]]></category>
		<category><![CDATA[TJX]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67526</guid>
		<description><![CDATA[• Garmin Ltd. (NASDAQ:GRMN) reported Q4 EPS of $0.83, lower than the Zacks Consensus Estimate of $0.87 per share. Revenues for the quarter fell 21% year-over-year to $838.0 million, missing the Zacks Consensus Estimate of $860.0 million • Chico’s FAS, Inc. (NYSE:CHS) reported Q4 EPS of $0.12, slightly lower than the Zacks Consensus Estimate of $0.13 per share. Revenues for the quarter rose 9% year-over-year to $475.0 million, above the Zacks Consensus Estimate of $473.0 million • Limited Brands (NYSE:LTD) reported Q4 EPS of $1.26, ex-items, beating the Zacks Consensus Estimate of $1.25 per share. Revenues for the quarter rose to $3.46 billion, above the Zacks  Consensus Estimate of $3.397 billion • Avago Technologies (NASDAQ:AVGO) reported Q1 EPS of $0.65, above the Zacks Consensus Estimate of $0.53 per share. Revenues for the quarter rose ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/24/chs-company-news-for-february-24-2011-corporate-summary/67526/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Reports Wider Loss</title>
		<link>http://www.stockbloghub.com/2010/10/29/vrtx-vertex-pharmaceuticals-reports-wider-loss/57047</link>
		<comments>http://www.stockbloghub.com/2010/10/29/vrtx-vertex-pharmaceuticals-reports-wider-loss/57047#comments</comments>
		<pubDate>Fri, 29 Oct 2010 16:06:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57047</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted a higher third-quarter loss (including stock-based compensation expense) of 99 cents per share, compared with the Zacks Consensus Estimate of a loss of 91 cents and the year-ago loss of 83 cents. Increased expenses related to the potential launch of telaprevir (being developed for the treatment of hepatitis C virus or HCV) led to the decline. Quarter in Detail Quarterly revenues amounted to $23.8 million, lower than the Zacks Consensus Estimate of $31 million and the year-ago figure of $25 million. Vertex Pharma’s revenues consist of royalty revenues (up 4% to $8.2 million) and collaborative revenues (down 9% to $15.6 million). The company receives royalty from GlaxoSmithKline plc (GSK) on sales of Lexiva, a HIV protease inhibitor. Collaborative revenues consist of reimbursements received by Vertex ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/29/vrtx-vertex-pharmaceuticals-reports-wider-loss/57047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Seeks Approval For Hepatitis C Treatment</title>
		<link>http://www.stockbloghub.com/2009/12/16/hgsi-human-genome-sciences-seeks-approval-for-hepatitis-c-treatment/23016</link>
		<comments>http://www.stockbloghub.com/2009/12/16/hgsi-human-genome-sciences-seeks-approval-for-hepatitis-c-treatment/23016#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:27:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23016</guid>
		<description><![CDATA[Human Genome Sciences, Inc. (HGSI) recently announced the submission of a Marketing Authorization Application, [MAA], to the European Medicines Agency (EMEA) seeking marketing approval of Joulferon (albinterferon alfa-2b) for treating chronic hepatitis C patients. The application was submitted by Novartis (NVS) with whom Human Genome entered into an exclusive global agreement for the development and commercialization of the drug in 2006. The application  for European approval includes data from two pivotal late-stage trials which showed that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys of Roche (RHHBY)) dosed once each week. The randomized, open-label, active-controlled, multi-center, non-inferiority studies, known as ACHIEVE 1 and ACHIEVE 2/3, evaluated albinterferon alfa-2b vs. peginterferon alfa-2a, in combination with ribavirin, for treating interferon-naïve patients with chronic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/hgsi-human-genome-sciences-seeks-approval-for-hepatitis-c-treatment/23016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Array BioPharma Sees Positive Results for ARRY-380</title>
		<link>http://www.stockbloghub.com/2009/12/14/arry-array-biopharma-sees-positive-results-for-arry-380/22765</link>
		<comments>http://www.stockbloghub.com/2009/12/14/arry-array-biopharma-sees-positive-results-for-arry-380/22765#comments</comments>
		<pubDate>Tue, 15 Dec 2009 01:21:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[ARQL]]></category>
		<category><![CDATA[ArQule Inc]]></category>
		<category><![CDATA[Array BioPharma]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22765</guid>
		<description><![CDATA[Recently, Array BioPharma Inc. (ARRY) announced positive interim results on its inhibitor, ARRY-380, from an early-stage, open-label, multiple dose trial in patients with advanced cancer. The company presented the results at the 2009 San Antonio Breast Cancer Symposium. The study is designed to evaluate the safety, tolerability and pharmacokinetics of ARRY-380 following daily oral administration to patients suffering from advanced cancer. The candidate, which has been effective in preclinical models of human breast cancer resulting in significant anti-tumor activity, is a selective, orally-active ErbB-2 inhibitor being evaluated by Array for cancer indications. ErbB-2 is a receptor kinase target that has been found to be over-expressed in breast cancer as well as other cancers like gastric and ovarian cancers. The interim results revealed that ARRY-380 showed evidence of tumor regression in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/14/arry-array-biopharma-sees-positive-results-for-arry-380/22765/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Posts Wider Loss</title>
		<link>http://www.stockbloghub.com/2009/10/27/vrtx-vertex-pharmaceuticals-posts-wider-loss/18922</link>
		<comments>http://www.stockbloghub.com/2009/10/27/vrtx-vertex-pharmaceuticals-posts-wider-loss/18922#comments</comments>
		<pubDate>Wed, 28 Oct 2009 01:40:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18922</guid>
		<description><![CDATA[Vertex Pharmaceuticals (VRTX) posted a loss of 83 cents per share in the third quarter, 3 cents wider than the Zacks Consensus Estimate of a loss of 80 cents. The company posted a loss of 92 cents per share in the year ago period. The wider than expected loss was mainly due to a significant increase in costs and lower revenues. Revenues declined to $24.9 million in the reported quarter from $31.6 million in the year ago period. Revenues consist of royalty revenues and collaborative and other research and development revenues. Lower revenues were primarily due to a decrease in collaborative revenues. Expenses increased mainly due to the increased size of the company’s workforce Incorporatedreased spending on late-stage clinical programs and increased stock-based compensation expenses. Research and development (R&#38;D) expenses increased ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/27/vrtx-vertex-pharmaceuticals-posts-wider-loss/18922/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANDS) Anadys Begins Mid-Stage Trial</title>
		<link>http://www.stockbloghub.com/2009/09/11/ands-anadys-begins-mid-stage-trial/14986</link>
		<comments>http://www.stockbloghub.com/2009/09/11/ands-anadys-begins-mid-stage-trial/14986#comments</comments>
		<pubDate>Fri, 11 Sep 2009 23:12:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Anadys Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANDS]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14986</guid>
		<description><![CDATA[Yesterday, Anadys Pharmaceuticals Inc. (ANDS) started a 12-week phase II trial of its ANA598 for hepatitis C patients. ANA 598 will be evaluated in combination with interferon-alpha and ribavirin (current standard of care) in the mid-stage study. Data from the trial is expected to be released at the end of this year and in the first two quarters of 2010. A total of 90 patients are planned to be enrolled in the study, with 30 patients receiving ANA598 and 15 receiving placebo at each dose level. The study would test 200 mg and 400 mg doses of the drug. In order to maximize early viral suppression, each patient would receive two 800 mg doses on the first day. The study would be conducted at various sites in the U.S. Chronic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/ands-anadys-begins-mid-stage-trial/14986/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

